Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study

References

• Haldorsen IS, Krossnes BK, Scheie D, Johanssen TB, Mella O, Espeland A. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989–2003. Cancer 2007;110:1803–14.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet 2009;374:1512–20.
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489–95.
   PubMed Web of Science ®Google Scholar
• Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504–10.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23:5034–43.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–47.
   PubMed Web of Science ®Google Scholar
• Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: Results of a phase II study. J Neuro Oncol 2009;91: 299–305.
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730–5.
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742–9.
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008;26:2512–8.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008;93:147–8.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Pract Res Clin Haematol 2012;25:119–30.
   PubMed Web of Science ®Google Scholar
• Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013; 98:765–70.
   PubMed Web of Science ®Google Scholar
• Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: A multi-institutional experience. J Clin Oncol 2009;27:3503–9.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 2011;22:2080–5.
   PubMed Web of Science ®Google Scholar